Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already
In this Issue Reflecting on UW Madison’s Fourth Annual Psychedelic Symposium MindMed Doses First Patient in Phase 3 LSD Program Beckley Psytech Shares Small Cut
Hardman: Right, so it’s just one example of creative thinking with regards to approval pathways for psychedelics. But the deeper point, presumably, is to poke
In this Issue Psychedelics Insiders Draw Up Trump 2.0 Wishlist Rick Doblin Reflects on Lykos’ Strategy as MAPS Settles with FDA Polish Medical Research Agency
In our latest interview, Psychedelic Alpha’s Josh Hardman speaks with Javier Muniz, MD, who recently left his post as Associate Director at the FDA’s Division of
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already
Earlier, we shared the high-level results of our Q3’24 Psychedelic Investor Survey, our third such survey. We also shared what investors are most excited about in the field.
(Editor’s note: In her first draft of this article, Dr. Alaina Jaster did not include herself, despite the central role she has played in challenging
Earlier, we shared the high-level results of our Q3’24 Psychedelic Investor Survey, our third such survey. Here, we take a closer look at investors’ qualitative responses
In this Issue Last-Minute Rule Changes, Opt-Outs, Ahead of Colorado’s Psychedelics Program Launch Cybin’s Impressive 12-Month Data Overshadowed by Small N and Controversial Marketing Move